Permutation Tests for Phase III Clinical Trials
The opinions and assertions expressed in this chapter are the private views of the authors. No endorsement by the Food and Drug Administration or the University of North Carolina at Chapel Hill is intended or should be inferred.
KeywordsPermutation Test Sample Space Adaptive Test Rejection Region Extreme Region
Unable to display preview. Download preview PDF.
- Ederer, F. (1975). Why do we need controls? Why do we need to randomize? American Journal of Ophthalmology 76, 758 - 762.Google Scholar
- Fox, S.M., Einhorn, L.H., Cox, E, Powell, N., and Abdy, A. (1993). Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. Journal of Clinical Oncology 11, 2391 - 2395.Google Scholar
- Ludbrook, J. and Dudley, H. (1998). Why permutation tests are superior to t and F tests in biomedical research. The American Statistician 52(2), 127132.Google Scholar
- Miller, R.G. (1980). Combining 2x2 contingency tables. In: Miller R.G., Efron B., Brown B.W., and Moses L.E., eds. Biostatistics Casebook. Wiley, New York.Google Scholar
- Permutt, T. and Hebel, J.R. (1989). Simultaneous-equation estimation in a clinical trial of the effect of smoking on birth weight. Biometrics 45, 619622.Google Scholar
- Placebo Working Group (1996). Placebo effects and research in alternative and conventional medicine. Chinese Journal of Integrated Medicine 2(2), 141148.Google Scholar
- Simon, R. (1982). Randomized clinical trials and research strategy. Cancer Treatment Reports 66 (5), 1083 - 1087.Google Scholar